Curasight A/S (NGM:CURAS)

Market Cap	198.17M
Revenue (ttm)	n/a
Net Income (ttm)	-49.52M
Shares Out	45.87M
EPS (ttm)	-2.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,814
Average Volume	139,118
Open	2.710
Previous Close	2.700
Day's Range	2.580 - 2.710
52-Week Range	1.800 - 13.400
Beta	0.03
RSI	60.78
Earnings Date	Aug 28, 2025

About Curasight

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. It develops uTREAT therapeutic solutions, which are in the pre-clinical stage to treat glioblastoma (brain cancer), as well as have completed the pre-clinical stage for the treatment of non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. The company also develops uTRACE diagnostic solutions, which are in Phase II to treat prostate cancer, as well as have completed Phase II for the treatment of glioblastoma (b...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2013
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: CURAS

Financial Performance

Financial numbers in DKK